Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
1094 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Rheumatoid Arthritis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Rheumatoid Arthritis - Pipeline Review, H2 2014', provides an overview of the Rheumatoid Arthritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rheumatoid Arthritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 12 Rheumatoid Arthritis Overview 13 Therapeutics Development 14 Rheumatoid Arthritis - Therapeutics under Development by Companies 16 Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes 36 Rheumatoid Arthritis - Pipeline Products Glance 40 Rheumatoid Arthritis - Products under Development by Companies 44 Rheumatoid Arthritis - Products under Investigation by Universities/Institutes 71 Rheumatoid Arthritis - Companies Involved in Therapeutics Development 74 Rheumatoid Arthritis - Therapeutics Assessment 298 Drug Profiles 327 Rheumatoid Arthritis - Recent Pipeline Updates 878 Rheumatoid Arthritis - Dormant Projects 997 Rheumatoid Arthritis - Discontinued Products 1028 Rheumatoid Arthritis - Product Development Milestones 1039 Appendix 1046
List of Tables Number of Products under Development for Rheumatoid Arthritis, H2 2014 61 Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2014 62 Number of Products under Development by Companies, H2 2014 64 Number of Products under Development by Companies, H2 2014 (Contd..1) 65 Number of Products under Development by Companies, H2 2014 (Contd..2) 66 Number of Products under Development by Companies, H2 2014 (Contd..3) 67 Number of Products under Development by Companies, H2 2014 (Contd..4) 68 Number of Products under Development by Companies, H2 2014 (Contd..5) 69 Number of Products under Development by Companies, H2 2014 (Contd..6) 70 Number of Products under Development by Companies, H2 2014 (Contd..7) 71 Number of Products under Development by Companies, H2 2014 (Contd..8) 72 Number of Products under Development by Companies, H2 2014 (Contd..9) 73 Number of Products under Development by Companies, H2 2014 (Contd..10) 74 Number of Products under Development by Companies, H2 2014 (Contd..11) 75 Number of Products under Development by Companies, H2 2014 (Contd..12) 76 Number of Products under Development by Companies, H2 2014 (Contd..13) 77 Number of Products under Development by Companies, H2 2014 (Contd..14) 78 Number of Products under Development by Companies, H2 2014 (Contd..15) 79 Number of Products under Development by Companies, H2 2014 (Contd..16) 80 Number of Products under Development by Companies, H2 2014 (Contd..17) 81 Number of Products under Development by Companies, H2 2014 (Contd..18) 82 Number of Products under Investigation by Universities/Institutes, H2 2014 84 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 85 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 86 Comparative Analysis by Late Stage Development, H2 2014 87 Comparative Analysis by Clinical Stage Development, H2 2014 88 Comparative Analysis by Early Stage Development, H2 2014 89 Comparative Analysis by Unknown Stage Development, H2 2014 90 Products under Development by Companies, H2 2014 91 Products under Development by Companies, H2 2014 (Contd..1) 92 Products under Development by Companies, H2 2014 (Contd..2) 93 Products under Development by Companies, H2 2014 (Contd..3) 94 Products under Development by Companies, H2 2014 (Contd..4) 95 Products under Development by Companies, H2 2014 (Contd..5) 96 Products under Development by Companies, H2 2014 (Contd..6) 97 Products under Development by Companies, H2 2014 (Contd..7) 98 Products under Development by Companies, H2 2014 (Contd..8) 99 Products under Development by Companies, H2 2014 (Contd..9) 100 Products under Development by Companies, H2 2014 (Contd..10) 101 Products under Development by Companies, H2 2014 (Contd..11) 102 Products under Development by Companies, H2 2014 (Contd..12) 103 Products under Development by Companies, H2 2014 (Contd..13) 104 Products under Development by Companies, H2 2014 (Contd..14) 105 Products under Development by Companies, H2 2014 (Contd..15) 106 Products under Development by Companies, H2 2014 (Contd..16) 107 Products under Development by Companies, H2 2014 (Contd..17) 108 Products under Development by Companies, H2 2014 (Contd..18) 109 Products under Development by Companies, H2 2014 (Contd..19) 110 Products under Development by Companies, H2 2014 (Contd..20) 111 Products under Development by Companies, H2 2014 (Contd..21) 112 Products under Development by Companies, H2 2014 (Contd..22) 113 Products under Development by Companies, H2 2014 (Contd..23) 114 Products under Development by Companies, H2 2014 (Contd..24) 115 Products under Development by Companies, H2 2014 (Contd..25) 116 Products under Development by Companies, H2 2014 (Contd..26) 117 Products under Investigation by Universities/Institutes, H2 2014 118 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 119 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 120 Rheumatoid Arthritis - Pipeline by 4SC AG, H2 2014 121 Rheumatoid Arthritis - Pipeline by AB Science, H2 2014 122 Rheumatoid Arthritis - Pipeline by AbbVie Inc., H2 2014 123 Rheumatoid Arthritis - Pipeline by Ablynx NV, H2 2014 124 Rheumatoid Arthritis - Pipeline by Acceleron Pharma, Inc., H2 2014 125 Rheumatoid Arthritis - Pipeline by AcurePharma AB, H2 2014 126 Rheumatoid Arthritis - Pipeline by Addex Therapeutics Ltd, H2 2014 127 Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd., H2 2014 128 Rheumatoid Arthritis - Pipeline by Aegera Therapeutics Inc., H2 2014 129 Rheumatoid Arthritis - Pipeline by Agilvax, Inc., H2 2014 130 Rheumatoid Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H2 2014 131 Rheumatoid Arthritis - Pipeline by Alloksys Life Sciences BV, H2 2014 132 Rheumatoid Arthritis - Pipeline by Almirall, S.A., H2 2014 133 Rheumatoid Arthritis - Pipeline by AlphaMab Co., Ltd, H2 2014 134 Rheumatoid Arthritis - Pipeline by Amgen Inc., H2 2014 135 Rheumatoid Arthritis - Pipeline by Amura Holdings Ltd., H2 2014 136 Rheumatoid Arthritis - Pipeline by Antyra, Inc., H2 2014 137 Rheumatoid Arthritis - Pipeline by Apexigen, Inc., H2 2014 138 Rheumatoid Arthritis - Pipeline by Aprogen, Inc., H2 2014 139 Rheumatoid Arthritis - Pipeline by arGentis Pharmaceuticals, LLC, H2 2014 140 Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 141 Rheumatoid Arthritis - Pipeline by Arthrogen BV, H2 2014 142 Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp., H2 2014 143 Rheumatoid Arthritis - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 144 Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc., H2 2014 145 Rheumatoid Arthritis - Pipeline by AstraZeneca PLC, H2 2014 146 Rheumatoid Arthritis - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 147 Rheumatoid Arthritis - Pipeline by Avesthagen Limited, H2 2014 148 Rheumatoid Arthritis - Pipeline by Avexxin AS, H2 2014 149 Rheumatoid Arthritis - Pipeline by Avipep Pty Ltd, H2 2014 150 Rheumatoid Arthritis - Pipeline by Axxam SpA, H2 2014 151 Rheumatoid Arthritis - Pipeline by Biocon Limited, H2 2014 152 Rheumatoid Arthritis - Pipeline by Bioiberica, S.A., H2 2014 153 Rheumatoid Arthritis - Pipeline by Biokine Therapeutics Ltd., H2 2014 154 Rheumatoid Arthritis - Pipeline by Bionomics Limited, H2 2014 155 Rheumatoid Arthritis - Pipeline by Biotest AG, H2 2014 156 Rheumatoid Arthritis - Pipeline by BioTherapeutics Inc., H2 2014 157 Rheumatoid Arthritis - Pipeline by Biotie Therapies Corp., H2 2014 158 Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 159 Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim Pharmaceuticals, Inc., H2 2014 160 Rheumatoid Arthritis - Pipeline by Bolder Biotechnology, Inc., H2 2014 161 Rheumatoid Arthritis - Pipeline by Bone Medical Limited, H2 2014 162 Rheumatoid Arthritis - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2014 163 Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2014 164 Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 165 Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc., H2 2014 166 Rheumatoid Arthritis - Pipeline by CEL-SCI Corporation, H2 2014 167 Rheumatoid Arthritis - Pipeline by Celgene Corporation, H2 2014 168 Rheumatoid Arthritis - Pipeline by Cellceutix Corporation, H2 2014 169 Rheumatoid Arthritis - Pipeline by Cellmid Limited, H2 2014 170 Rheumatoid Arthritis - Pipeline by Celltrion, Inc., H2 2014 171 Rheumatoid Arthritis - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 172 Rheumatoid Arthritis - Pipeline by Cellworks Group, Inc., H2 2014 173 Rheumatoid Arthritis - Pipeline by CG Pharmaceuticals, Inc., H2 2014 174 Rheumatoid Arthritis - Pipeline by ChemoCentryx, Inc., H2 2014 175 Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H2 2014 176 Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H2 2014 177 Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 178 Rheumatoid Arthritis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 179 Rheumatoid Arthritis - Pipeline by CIMAB S.A., H2 2014 180 Rheumatoid Arthritis - Pipeline by CLL Pharma, H2 2014 181 Rheumatoid Arthritis - Pipeline by Compugen Ltd., H2 2014 182 Rheumatoid Arthritis - Pipeline by Coronado Biosciences, Inc., H2 2014 183 Rheumatoid Arthritis - Pipeline by Covagen AG, H2 2014 184 Rheumatoid Arthritis - Pipeline by Creabilis SA, H2 2014 185 Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 186 Rheumatoid Arthritis - Pipeline by Diurnal Ltd, H2 2014 187 Rheumatoid Arthritis - Pipeline by Dong-A Socio Group, H2 2014 188 Rheumatoid Arthritis - Pipeline by Dynamix Pharmaceuticals Ltd., H2 2014 189 Rheumatoid Arthritis - Pipeline by Effimune SAS, H2 2014 190 Rheumatoid Arthritis - Pipeline by Eisai Co., Ltd., H2 2014 191 Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H2 2014 192 Rheumatoid Arthritis - Pipeline by Emergent BioSolutions Inc., H2 2014 193 Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H2 2014 194 Rheumatoid Arthritis - Pipeline by Endocyte, Inc., H2 2014 195 Rheumatoid Arthritis - Pipeline by Ensemble Therapeutics Corporation, H2 2014 196 Rheumatoid Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 197 Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 198 Rheumatoid Arthritis - Pipeline by Farmacija d.o.o. Tuzla, H2 2014 199 Rheumatoid Arthritis - Pipeline by Five Prime Therapeutics, Inc., H2 2014 200 Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc., H2 2014 201 Rheumatoid Arthritis - Pipeline by Galapagos NV, H2 2014 202 Rheumatoid Arthritis - Pipeline by GeneFrontier Corporation, H2 2014 203 Rheumatoid Arthritis - Pipeline by Genentech, Inc., H2 2014 204 Rheumatoid Arthritis - Pipeline by Genor BioPharma Co., Ltd., H2 2014 205 Rheumatoid Arthritis - Pipeline by Genosco, H2 2014 206 Rheumatoid Arthritis - Pipeline by Gilead Sciences, Inc., H2 2014 207 Rheumatoid Arthritis - Pipeline by GlaxoSmithKline plc, H2 2014 208 Rheumatoid Arthritis - Pipeline by Griffin Discoveries BV, H2 2014 209 Rheumatoid Arthritis - Pipeline by Handok Inc., H2 2014 210 Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 211 Rheumatoid Arthritis - Pipeline by Hanwha Chemical Co., Ltd., H2 2014 212 Rheumatoid Arthritis - Pipeline by Huabo Biopharm Co., Ltd., H2 2014 213 Rheumatoid Arthritis - Pipeline by Hutchison MediPharma Limited, H2 2014 214 Rheumatoid Arthritis - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 215 Rheumatoid Arthritis - Pipeline by IMMD Inc., H2 2014 216 Rheumatoid Arthritis - Pipeline by Immune Response BioPharma, Inc., H2 2014 217 Rheumatoid Arthritis - Pipeline by ImmunoFrontier, Inc., H2 2014 218 Rheumatoid Arthritis - Pipeline by Immupharma Plc, H2 2014 219 Rheumatoid Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 220 Rheumatoid Arthritis - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 221 Rheumatoid Arthritis - Pipeline by Innate Pharma SA, H2 2014 222 Rheumatoid Arthritis - Pipeline by Innovent Biologics, Inc., H2 2014 223 Rheumatoid Arthritis - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 224 Rheumatoid Arthritis - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 225 Rheumatoid Arthritis - Pipeline by Invion Limited, H2 2014 226 Rheumatoid Arthritis - Pipeline by InvivoGen Therapeutics, H2 2014 227 Rheumatoid Arthritis - Pipeline by Johnson & Johnson, H2 2014 228 Rheumatoid Arthritis - Pipeline by Kadmon Corporation, LLC, H2 2014 229 Rheumatoid Arthritis - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 230 Rheumatoid Arthritis - Pipeline by KAHR medical Ltd., H2 2014 231 Rheumatoid Arthritis - Pipeline by Kainos Medicine, Inc., H2 2014 232 Rheumatoid Arthritis - Pipeline by Kineta, Inc., H2 2014 233 Rheumatoid Arthritis - Pipeline by LG Life Sciences, Ltd., H2 2014 234 Rheumatoid Arthritis - Pipeline by Lupin Limited, H2 2014 235 Rheumatoid Arthritis - Pipeline by Lycera Corp., H2 2014 236
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
